Prescriptions for Ironwood Pharmaceuticals Inc. and Allergan plc's Linzess (linaclotide) have been written for 1.5 million unique patients with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) since the drug was launched at the end of 2012.